Lovett returns to the Board after previously serving from 2015-2022
PHILADELPHIA — (Mar. 11, 2026) — The Wistar Institute, a global leader in biomedical research in cancer, immunology and infectious disease, is pleased to welcome James Lovett to its Board of Trustees. Lovett comes to the role with a strong background in the life science industry and a prior 7-year term on Wistar’s Board of Trustees.
Lovett served for seven years as CEO of Myonex Inc., a leading global clinical trial supply company based in Horsham, Pennsylvania, where he previously served as chief operating officer. Prior to Myonex, He served 14 years as corporate senior vice president of Covance Inc., a global drug development services company based in Princeton, N.J., where he was general counsel and had responsibility for three different Covance business units.
Lovett previously served on The Wistar Institute Board of Trustees from 2015 to 2022 and currently serves on the boards of Myonex and ChyloMetis. He has also served on the boards of BioClinica, Inc., the National Association for Biomedical Research, and the Pennsylvania Society for Biomedical Research as board chairman, among others.
“We are delighted to welcome James back to The Wistar Institute Board of Trustees,” said Dr. Dario Altieri, president and CEO of The Wistar Institute. “His extensive expertise and broad industry insight are tremendous assets. Having previously served on our Board, James brings a deep understanding of our mission, our science, and our culture. We look forward to his leadership as we advance discoveries with meaningful impact.”
“I am delighted to rejoin The Wistar Institute Board of Trustees,” said Lovett. “We are at a critical juncture in biomedical research, and Wistar is at the forefront of driving tremendous advancements for the benefit of humanity.”
Lovett received his JD from Harvard University and his BA from Northwestern University.
ABOUT THE WISTAR INSTITUTE:
The Wistar Institute is the nation’s first independent nonprofit institution devoted exclusively to foundational biomedical research and training. Since 1972, the Institute has held National Cancer Institute (NCI)-designated Cancer Center status. Through a culture and commitment to biomedical collaboration and innovation, Wistar science leads to breakthrough early-stage discoveries and life science sector start-ups. Wistar scientists are dedicated to solving some of the world’s most challenging problems in the field of cancer and immunology, advancing human health through early-stage discovery and training the next generation of biomedical researchers. wistar.org
